The timing of low-dose naltrexone (LDN) administration is a crucial factor influencing its effectiveness. Administering LDN at the appropriate time of day, typically in the evening, can optimize its interaction with the body’s natural endorphin cycles. This strategic scheduling is intended to maximize the brief blockade of opioid receptors, leading to a subsequent increase in endorphin production. For instance, taking the medication at night allows for the blockade to occur during sleep, theoretically leading to a more pronounced rebound effect of endorphin release in the morning.
Optimal scheduling contributes to the intended benefits by promoting the modulation of the immune system and the reduction of inflammation. The historical context of LDN usage reveals that the understanding of its pharmacodynamics and the importance of timing has evolved over time. Initial research focused primarily on its opioid antagonist properties at higher doses; however, subsequent investigations highlighted the potential of low doses to influence immune function through transient opioid receptor blockade. Adhering to a consistent schedule is viewed as paramount for achieving sustained therapeutic effects and for minimizing potential side effects.
